Multiple System Atrophy Therapeutics Market Size, Global Industry Growth, Share, Analysis and Forecast 2025-2033
Description
The Global Multiple System Atrophy Therapeutics Market Size accounted for USD 141.2 Million in 2024 and is estimated to achieve a market size of USD 213.3 Million by 2033 growing at a CAGR of 4.8% from 2025 to 2033.
Multiple System Atrophy (MSA) is a rare, neurodegenerative disorder that primarily affects the autonomic nervous system and movement control. It shares several clinical features with other neurodegenerative disorders, such as Parkinson's disease, but progresses more rapidly and has a less favorable prognosis. The pathophysiology of MSA involves the accumulation of alpha-synuclein, which leads to neuronal death and the degeneration of various brain regions, particularly the basal ganglia, cerebellum, and brainstem. This results in a variety of symptoms, including motor dysfunction, autonomic failure, and cognitive impairment. Due to its heterogeneous clinical presentation and lack of definitive biomarkers, MSA is often difficult to diagnose, making early intervention a challenge. Currently, there is no disease-modifying therapy for MSA, and treatment is mainly symptomatic, aiming to alleviate the burden of the disease and improve the quality of life of affected individuals.
The global Multiple System Atrophy therapeutics market has seen notable advancements in recent years, driven by growing awareness, research into disease mechanisms, and the potential for novel treatments. The market can be segmented based on drug class, treatment type, and geography. Drug classes currently in the therapeutic pipeline include symptomatic treatments, neuroprotective therapies, and disease-modifying therapies. Symptomatic treatments primarily focus on managing the motor symptoms and autonomic dysfunction associated with MSA, utilizing medications such as levodopa and other dopaminergic agents, as well as alpha-adrenergic blockers for autonomic symptoms. However, these therapies offer limited benefit and are not curative, highlighting the urgent need for new therapeutic approaches.
Multiple System Atrophy Therapeutics Market Segmentation
The worldwide market for multiple system atrophy therapeutics is split based on product, mechanism of action, end-user, and geography.
Multiple System Atrophy Therapeutics Market By Product
Anle-138b
Azd-3241
Cs-10br05
Npt-20011
Pbt-434
Pd-01
Multiple System Atrophy Therapeutics Market By Mechanism of Action
Suppressing inflammation
Restoring neuronal function
Targeting disease pathways
Protecting against neurotoxicity
Multiple System Atrophy Therapeutics Market By End-User
Hospital
Clinic
Others
Multiple System Atrophy Therapeutics Market Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
The Middle East & Africa
South Africa
GCC Countries
Rest of the Middle East & Africa (ME&A)
Multiple System Atrophy Therapeutics Market Players
Some of the top multiple system atrophy therapeutics companies offered in our report includes Prana Biotechnology Ltd, Sumitomo Dainippon Pharma Co., Ltd, AstraZeneca Plc, MitoDys Therapeutics Ltd, Modag GmbH, Biohaven Pharmaceuticals, Inc, Theravance Biopharma, Inc, Neuropore Therapies Inc, AFFiRiS AG, ProMIS Neurosciences Inc, and Corestem Inc.
Multiple System Atrophy (MSA) is a rare, neurodegenerative disorder that primarily affects the autonomic nervous system and movement control. It shares several clinical features with other neurodegenerative disorders, such as Parkinson's disease, but progresses more rapidly and has a less favorable prognosis. The pathophysiology of MSA involves the accumulation of alpha-synuclein, which leads to neuronal death and the degeneration of various brain regions, particularly the basal ganglia, cerebellum, and brainstem. This results in a variety of symptoms, including motor dysfunction, autonomic failure, and cognitive impairment. Due to its heterogeneous clinical presentation and lack of definitive biomarkers, MSA is often difficult to diagnose, making early intervention a challenge. Currently, there is no disease-modifying therapy for MSA, and treatment is mainly symptomatic, aiming to alleviate the burden of the disease and improve the quality of life of affected individuals.
The global Multiple System Atrophy therapeutics market has seen notable advancements in recent years, driven by growing awareness, research into disease mechanisms, and the potential for novel treatments. The market can be segmented based on drug class, treatment type, and geography. Drug classes currently in the therapeutic pipeline include symptomatic treatments, neuroprotective therapies, and disease-modifying therapies. Symptomatic treatments primarily focus on managing the motor symptoms and autonomic dysfunction associated with MSA, utilizing medications such as levodopa and other dopaminergic agents, as well as alpha-adrenergic blockers for autonomic symptoms. However, these therapies offer limited benefit and are not curative, highlighting the urgent need for new therapeutic approaches.
Multiple System Atrophy Therapeutics Market Segmentation
The worldwide market for multiple system atrophy therapeutics is split based on product, mechanism of action, end-user, and geography.
Multiple System Atrophy Therapeutics Market By Product
Anle-138b
Azd-3241
Cs-10br05
Npt-20011
Pbt-434
Pd-01
Multiple System Atrophy Therapeutics Market By Mechanism of Action
Suppressing inflammation
Restoring neuronal function
Targeting disease pathways
Protecting against neurotoxicity
Multiple System Atrophy Therapeutics Market By End-User
Hospital
Clinic
Others
Multiple System Atrophy Therapeutics Market Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
The Middle East & Africa
South Africa
GCC Countries
Rest of the Middle East & Africa (ME&A)
Multiple System Atrophy Therapeutics Market Players
Some of the top multiple system atrophy therapeutics companies offered in our report includes Prana Biotechnology Ltd, Sumitomo Dainippon Pharma Co., Ltd, AstraZeneca Plc, MitoDys Therapeutics Ltd, Modag GmbH, Biohaven Pharmaceuticals, Inc, Theravance Biopharma, Inc, Neuropore Therapies Inc, AFFiRiS AG, ProMIS Neurosciences Inc, and Corestem Inc.
Table of Contents
250 Pages
- CHAPTER 1.Industry Overview of Multiple System Atrophy Therapeutics Market
- 1.1.Definition and Scope
- 1.2.Summary
- CHAPTER 2.Research Approach
- 2.1.Methodology
- 2.2.Data Source
- CHAPTER 3.Market Dynamics And Competition Analysis
- 3.1.Market Drivers
- 3.2.Restraints and Challenges
- 3.3.Growth Opportunities
- 3.4.Porter’s Five Forces Analysis
- 3.4.1.Bargaining Power of Suppliers
- 3.4.2.Bargaining Power of Buyers
- 3.4.3.Threat of Substitute
- 3.4.4.Threat of New Entrants
- 3.4.5.Degree of Competition
- 3.5.Market Concentration Ratio and Market Maturity Analysis of Multiple System Atrophy Therapeutics Market
- 3.5.1.Go To Market Strategy
- 3.5.1.1.Introduction
- 3.5.1.2.Growth
- 3.5.1.3.Maturity
- 3.5.1.4.Saturation
- 3.5.1.5.Possible Development
- 3.6.Technological Roadmap for Multiple System Atrophy Therapeutics Market
- 3.7.Value Chain Analysis
- 3.7.1.List of Key Manufacturers
- 3.7.2.List of Customers
- 3.7.3.Level of Integration
- 3.8.Cost Structure Analysis
- 3.8.1.Price Trend of Key Raw Materials
- 3.8.2.Raw Material Suppliers
- 3.8.3.Proportion of Manufacturing Cost Structure
- 3.8.3.1.Raw Material
- 3.8.3.2.Labor Cost
- 3.8.3.3.Manufacturing Expense
- 3.9.Regulatory Compliance
- 3.10.Competitive Landscape, 2024
- 3.10.1.Player Positioning Analysis
- 3.10.2.Key Strategies Adopted By Leading Players
- CHAPTER 4.Manufacturing Plant Analysis
- 4.1.Manufacturing Plant Location and Establish Date of Major Manufacturers in 2024
- 4.2.R&D Status of Major Manufacturers in 2024
- CHAPTER 5.Multiple System Atrophy Therapeutics Market By Product
- 5.1.Introduction
- 5.2.Multiple System Atrophy Therapeutics Revenue By Product
- 5.2.1.Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast, By Product, 2021-2033
- 5.2.2.Anle-138b
- 5.2.2.1.Anle-138b Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 5.2.3.Azd-3241
- 5.2.3.1.Azd-3241 Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 5.2.4.Cs-10br05
- 5.2.4.1.Cs-10br05 Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 5.2.5.Npt-20011
- 5.2.5.1.Npt-20011 Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 5.2.6.Pbt-434
- 5.2.6.1.Pbt-434 Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 5.2.7.Pd-01
- 5.2.7.1.Pd-01 Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- CHAPTER 6.Multiple System Atrophy Therapeutics Market By Mechanism of action
- 6.1.Introduction
- 6.2.Multiple System Atrophy Therapeutics Revenue By Mechanism of action
- 6.2.1.Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast, By Mechanism of action, 2021-2033
- 6.2.2.Suppressing Inflammation
- 6.2.2.1.Suppressing Inflammation Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 6.2.3.Restoring Neuronal Function
- 6.2.3.1.Restoring Neuronal Function Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 6.2.4.Targeting Disease Pathways
- 6.2.4.1.Targeting Disease Pathways Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 6.2.5.Protecting Against Neurotoxicity
- 6.2.5.1.Protecting Against Neurotoxicity Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- CHAPTER 7.Multiple System Atrophy Therapeutics Market By End-user
- 7.1.Introduction
- 7.2.Multiple System Atrophy Therapeutics Revenue By End-user
- 7.2.1.Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast, By End-user, 2021-2033
- 7.2.2.Hospital
- 7.2.2.1.Hospital Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 7.2.3.Clinic
- 7.2.3.1.Clinic Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 7.2.4.Others
- 7.2.4.1.Others Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- CHAPTER 8.North America Multiple System Atrophy Therapeutics Market By Country
- 8.1.North America Multiple System Atrophy Therapeutics Market Overview
- 8.2.U.S.
- 8.2.1.U.S. Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 8.2.2.U.S. Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 8.2.3.U.S. Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End-Use, 2021-2033
- 8.3.Canada
- 8.3.1.Canada Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 8.3.2.Canada Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 8.3.3.Canada Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 8.4.North America PEST Analysis
- CHAPTER 9.Europe Multiple System Atrophy Therapeutics Market By Country
- 9.1.Europe Multiple System Atrophy Therapeutics Market Overview
- 9.2.U.K.
- 9.2.1.U.K. Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 9.2.2.U.K. Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 9.2.3.U.K. Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 9.3.Germany
- 9.3.1.Germany Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 9.3.2.Germany Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 9.3.3.Germany Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 9.4.France
- 9.4.1.France Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 9.4.2.France Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 9.4.3.France Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 9.5.Spain
- 9.5.1.Spain Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 9.5.2.Spain Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 9.5.3.Spain Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 9.6.Rest of Europe
- 9.6.1.Rest of Europe Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 9.6.2.Rest of Europe Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 9.6.3.Rest of Europe Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 9.7.Europe PEST Analysis
- CHAPTER 10.Asia Pacific Multiple System Atrophy Therapeutics Market By Country
- 10.1.Asia Pacific Multiple System Atrophy Therapeutics Market Overview
- 10.2.China
- 10.2.1.China Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 10.2.2.China Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 10.2.3.China Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 10.3.Japan
- 10.3.1.Japan Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 10.3.2.Japan Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 10.3.3.Japan Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 10.4.India
- 10.4.1.India Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 10.4.2.India Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 10.4.3.India Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 10.5.Australia
- 10.5.1.Australia Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 10.5.2.Australia Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 10.5.3.Australia Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 10.6.South Korea
- 10.6.1.South Korea Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 10.6.2.South Korea Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 10.6.3.South Korea Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 10.7.Rest of Asia-Pacific
- 10.7.1.Rest of Asia-Pacific Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 10.7.2.Rest of Asia-Pacific Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 10.7.3.Rest of Asia-Pacific Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 10.8.Asia Pacific PEST Analysis
- CHAPTER 11.Latin America Multiple System Atrophy Therapeutics Market By Country
- 11.1.Latin America Multiple System Atrophy Therapeutics Market Overview
- 11.2.Brazil
- 11.2.1.Brazil Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 11.2.2.Brazil Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 11.2.3.Brazil Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 11.3.Mexico
- 11.3.1.Mexico Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 11.3.2.Mexico Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 11.3.3.Mexico Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 11.4.Rest of Latin America
- 11.4.1.Rest of Latin America Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 11.4.2.Rest of Latin America Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 11.4.3.Rest of Latin America Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 11.5.Latin America PEST Analysis
- CHAPTER 12.Middle East & Africa Multiple System Atrophy Therapeutics Market By Country
- 12.1.Middle East & Africa Multiple System Atrophy Therapeutics Market Overview
- 12.2.GCC
- 12.2.1.GCC Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 12.2.2.GCC Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 12.2.3.Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 12.3.South Africa
- 12.3.1.South Africa Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 12.3.2.South Africa Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 12.3.3.South Africa Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 12.4.Rest of Middle East & Africa
- 12.4.1.Rest of Middle East & Africa Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Product, 2021-2033
- 12.4.2.Rest of Middle East & Africa Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By Mechanism of action, 2021-2033
- 12.4.3.Rest of Middle East & Africa Multiple System Atrophy Therapeutics Revenue (USD Million) and Forecast By End Use, 2021-2033
- 12.5.Middle East & Africa PEST Analysis
- CHAPTER 13.Player Analysis Of Multiple System Atrophy Therapeutics Market
- 13.1.Multiple System Atrophy Therapeutics Market Company Share Analysis
- 13.2.Competition Matrix
- 13.2.1.Competitive Benchmarking of key players by price, presence, market share, and R&D investment
- 13.2.2.New Product Launches and Product Enhancements
- 13.2.3.Mergers And Acquisition In Global Multiple System Atrophy Therapeutics Market
- 13.2.4.Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
- CHAPTER 14.Company Profile
- 14.1.Prana Biotechnology Ltd
- 14.1.1.Company Snapshot
- 14.1.2.Business Overview
- 14.1.3.Financial Overview
- 14.1.3.1.Revenue (USD Million), 2024
- 14.1.3.2.Prana Biotechnology Ltd., 2024 Multiple System Atrophy Therapeutics Business Regional Distribution
- 14.1.4.Product /Service and Specification
- 14.1.5.Recent Developments & Business Strategy
- 14.2.Sumitomo Dainippon Pharma Co., Ltd
- 14.3.AstraZeneca Plc
- 14.4.MitoDys Therapeutics Ltd
- 14.5.Modag GmbH
- 14.6.Biohaven Pharmaceuticals, Inc
- 14.7.Theravance Biopharma, Inc
- 14.8.Neuropore Therapies Inc
- 14.9.AFFiRiS AG
- 14.10.ProMIS Neurosciences Inc
- 14.11.Corestem Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
